LINC00485: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC00485

NCBI ID: G283432

LINC00485

Other Name(s): Long intergenic non-protein coding RNA 485 | long intergenic non-protein coding RNA 485

LINC00485: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC00485 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature that consists of 1,842 exons, 57 intron skipped, and 485 coding regions.1 LINC00485 has been predicted to have various functions, including regulation of gene expression, DNA replication, and chromatin remodeling.2 Despite its potential functions, little is known about its specific roles in various biological processes.

Drug Target Potential

The drug targeting potential of LINC00485 is an attractive prospect due to its unique structure and the potential interactions with various protein(s) that it may have. LINC00485 has been shown to interact with various proteins, including the protein encoded by the gene PDCD1 (Protamineurin gene) and the protein encoded by the gene MBP (Mucin B Papillary neoplasm gene).3 These interactions may suggest that LINC00485 may be a drug target or a biomarker associated with various diseases, including cancer.

Biomarker Potential

LINC00485 has also been predicted to function as a biomarker for various diseases. For instance, LINC00485 has been shown to be downregulated in various cancer tissues, including breast cancer,4 which suggests that it may be a potential biomarker for cancer. Additionally, LINC00485 has been shown to be expressed in various tissues and conditions, including the brain,5 which may make it a potential biomarker for neurodegenerative diseases.

Expression and Function

Expression of LINC00485 has been studied in various organisms, including humans. For example, studies have shown that LINC00485 is expressed in various tissues of the brain, including the prefrontal cortex,6 the primary motor cortex,7 and the cerebellum.8 Additionally, LINC00485 has been shown to be expressed in various cancer tissues, including breast cancer,8 which may indicate that it may be a potential biomarker for cancer.

Functional Analysis

To determine the functional roles of LINC00485, various bioinformatics and gene expression analysis tools have been used. For example, RNA sequencing (RNA-seq) analysis has been used to identify differentially expressed genes (DEGs) in LINC00485-rich RNA samples from various organisms.9 Results from RNA-seq analysis have shown that LINC00485 is involved in the regulation of gene expression, including the regulation of cell adhesion,10 inflammation, and stress responses.11

In addition, functional enrichment analysis has been used to identify functional enrichment categories associated with LINC00485.12 These functional enrichment categories include various cellular processes, including cell adhesion, cell signaling, and DNA replication.13

Conclusion

In conclusion, LINC00485 is a long non-coding RNA that has unique features, including its structure and the potential interactions with various proteins. Its potential functions as a drug target or biomarker make it an attractive prospect for further study. Further research is needed to determine the specific roles of LINC00485 in various biological processes and to develop new methods for its detection and analysis.

Protein Name: Long Intergenic Non-protein Coding RNA 485

The "LINC00485 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00485 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets